IRVINE, Calif. (AP) — Specialty drugmaker Allergan is buying migraine headache drug developer MAP Pharmaceuticals Inc. for about $882.5 million as it looks to expand its migraine treatments.

MAP’s Levadex is an oral drug for the potential treatment of migraine headaches in adults. It is currently under review with the Food and Drug Administration.